Q2 2025 CorMedix Inc Earnings Call Transcript

Aug 7, 2025 / 12:30 PM GMT

Release Date Price: $10.81 (-9.54%)

Transcript 10-Q8-K

Key Points

Positve

Cormedix Inc (CRMD) announced the acquisition of Menta Therapeutics, which is expected to be transformational, creating a diversified specialty pharmaceutical company.
The acquisition is expected to be near-term accretive with double-digit EPS accretion in 2026, driving mid to long-term revenue and cash flow growth.
The company is guiding full-year 2025 revenue of $305 to $335 million, with significant contributions from Defendas sales.
Cormedix Inc (CRMD) reported a positive net income of $19.8 million for Q2 2025, compared to a net loss in the same quarter of 2024.
The company has a strong cash position with cash and cash equivalents of $190.7 million as of June 30, 2025, and has strengthened its balance sheet with recent financing activities.

Negative

Operating expenses increased by 18% in Q2 2025 compared to the same period in 2024, driven by higher R&D and G&A expenses.
There is uncertainty regarding the pace of the system-wide rollout of Defendas by the LDO customer, which could impact revenue projections.
The acquisition of Menta Therapeutics involves integration challenges and potential integration expenses, which are not yet fully detailed.
The competitive landscape in the anti-infective space, particularly in the inpatient setting, poses challenges for the newly acquired portfolio.
There is limited visibility into the potential risks associated with ongoing collaborations and the regulatory environment, which could affect future growth.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRMD.OQ - CorMedix Inc
Q2 2025 CorMedix Inc Earnings Call
Aug 07, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Core Medics Inc. 2nd quarter 2025 financial results conference call.

All participants will be in listen-only mode. Should you need assistance, please know what conference specialists are pressing the star key followed by 0.

After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on your telephone keypad. To TRY your question, please press star, then 2. Please note this event is being recorded. Right now I'll turn the conference over to Daniel Ferry, managing director of Lifestyle advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.